Dyadic International, Inc. engages in developing a gene expression platform for producing commercial quantities of industrial enzymes and other proteins. It focuses on further improving and applying its proprietary C1 technology, which is used in the discovery, development, and manufacture of biologic medicines and vaccines. Read More The company was founded by Mark A. Emalfarb in 1979 and is headquartered in Jupiter, FL. DYAI is listed on the OTCQX U.S. Premier market tier. OTC market data is provided by OTC Markets Group, Inc (otcmarkets.com).